Brief: Avenue Therapeutics Reports Q1 2023 Financial Results
12/05/2023 13:47
May 12 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS INC - QTRLY LOSS PER SHARE $1.37
Source text for Eikon: ID:nGNXsqywM
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary